aboutsummaryrefslogtreecommitdiffstats
path: root/skate/testdata/release/mgxkqlohmbhfpedxwg3s5jhrrq
blob: d231e5cfc62170c5cdbb2cf6c0bf94e1d67caa19 (plain)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
{
  "abstracts": [],
  "contribs": [
    {
      "extra": {
        "seq": "first"
      },
      "index": 0,
      "raw_name": "Anna K. Paulsson",
      "role": "author"
    },
    {
      "index": 1,
      "raw_name": "Adam Garsa",
      "role": "author"
    }
  ],
  "ext_ids": {
    "doi": "10.1007/978-3-319-62642-0_36"
  },
  "extra": {
    "container_name": "Handbook of Evidence-Based Radiation Oncology",
    "crossref": {
      "license": [
        {
          "URL": "http://www.springer.com/tdm",
          "content-version": "unspecified",
          "delay-in-days": 0,
          "start": "2018-01-01T00:00:00Z"
        },
        {
          "URL": "http://www.springer.com/tdm",
          "content-version": "unspecified",
          "delay-in-days": 0,
          "start": "2018-01-01T00:00:00Z"
        }
      ],
      "type": "book-chapter"
    }
  },
  "ident": "mgxkqlohmbhfpedxwg3s5jhrrq",
  "pages": "749-760",
  "publisher": "Springer International Publishing",
  "refs": [
    {
      "container_name": "Lancet Oncol",
      "extra": {
        "authors": [
          "KM Ardeshna"
        ],
        "doi": "10.1016/s1470-2045(14)70027-0",
        "unstructured": "Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomized phase 3 trial. Lancet Oncol. 2014;15(4):424–35.",
        "volume": "15"
      },
      "index": 0,
      "key": "36_CR1",
      "locator": "424",
      "year": 2014
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "SF Barrington"
        ],
        "doi": "10.1200/jco.2013.53.5229",
        "issue": "27",
        "unstructured": "Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–58.",
        "volume": "32"
      },
      "index": 1,
      "key": "36_CR2",
      "locator": "3048",
      "year": 2014
    },
    {
      "container_name": "International Journal of Radiation Oncology*Biology*Physics",
      "extra": {
        "authors": [
          "Tithi Biswas"
        ],
        "doi": "10.1016/j.ijrobp.2009.04.036",
        "unstructured": "Biswas T, et al. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. IJROBP. 2010;77(1):79–85.",
        "volume": "77"
      },
      "index": 2,
      "key": "36_CR1008",
      "locator": "79",
      "year": 2010
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "C Bonnet"
        ],
        "doi": "10.1200/jco.2006.07.0722",
        "unstructured": "Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25(7):787–92.",
        "volume": "25"
      },
      "index": 3,
      "key": "36_CR3",
      "locator": "787",
      "year": 2007
    },
    {
      "container_name": "Cancer",
      "extra": {
        "authors": [
          "BA Campbell"
        ],
        "doi": "10.1002/cncr.25117",
        "issue": "16",
        "unstructured": "Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma : involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–806.",
        "volume": "116"
      },
      "index": 4,
      "key": "36_CR4",
      "locator": "3797",
      "year": 2010
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "BD Cheson"
        ],
        "doi": "10.1200/jco.2013.54.8800",
        "issue": "27",
        "unstructured": "Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.",
        "volume": "32"
      },
      "index": 5,
      "key": "36_CR5",
      "locator": "3059",
      "year": 2014
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "B Coiffier"
        ],
        "doi": "10.1056/nejmoa011795",
        "unstructured": "Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma. N Engl J Med. 2002;346:235–42.",
        "volume": "346"
      },
      "index": 6,
      "key": "36_CR6",
      "locator": "235",
      "year": 2002
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "B Coiffier"
        ],
        "issue": "suppl 18S",
        "unstructured": "Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25(suppl 18S):443s. Abstract 8009.",
        "volume": "25"
      },
      "index": 7,
      "key": "36_CR7",
      "locator": "443s",
      "year": 2007
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "M Federico"
        ],
        "doi": "10.1200/jco.2008.21.3991",
        "issue": "27",
        "unstructured": "Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymhpma Prognostic Factor Project. J Clin Oncol. 2009;27(27):4555–62.",
        "volume": "27"
      },
      "index": 8,
      "key": "36_CR8",
      "locator": "4555",
      "year": 2009
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "RI Fisher"
        ],
        "doi": "10.1056/nejm199304083281404",
        "unstructured": "Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–6.",
        "volume": "328"
      },
      "index": 9,
      "key": "36_CR9",
      "locator": "1002",
      "year": 1993
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "C Guglielmi"
        ],
        "doi": "10.1200/jco.1998.16.10.3264",
        "unstructured": "Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264–9.",
        "volume": "16"
      },
      "index": 10,
      "key": "36_CR10",
      "locator": "3264",
      "year": 1998
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "R Haas"
        ],
        "doi": "10.1200/jco.2003.09.542",
        "issue": "13",
        "unstructured": "Haas R, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474–80.",
        "volume": "21"
      },
      "index": 11,
      "key": "36_CR11",
      "locator": "2474",
      "year": 2003
    },
    {
      "container_name": "Journal of Clinical Oncology",
      "extra": {
        "authors": [
          "Gerhard Held"
        ],
        "doi": "10.1200/jco.2012.48.0467",
        "issue": "32",
        "unstructured": "Held G, et al. Impact of rituxumab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. JCO. 2013;31(32):4115–22.",
        "volume": "31"
      },
      "index": 12,
      "key": "36_CR1005",
      "locator": "4115",
      "year": 2013
    },
    {
      "container_name": "Journal of Clinical Oncology",
      "extra": {
        "authors": [
          "Gerhard Held"
        ],
        "doi": "10.1200/jco.2013.51.4505",
        "issue": "11",
        "unstructured": "Held G, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. JCO. 2014;32(11):1112–8",
        "volume": "32"
      },
      "index": 13,
      "key": "36_CR1006",
      "locator": "1112",
      "year": 2014
    },
    {
      "container_name": "Blood",
      "extra": {
        "authors": [
          "W Hiddemann"
        ],
        "doi": "10.1182/blood-2005-01-0016",
        "unstructured": "Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab assed to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patient with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106:3725–32.",
        "volume": "106"
      },
      "index": 14,
      "key": "36_CR12",
      "locator": "3725",
      "year": 2005
    },
    {
      "container_name": "Bone Marrow Transplantation",
      "extra": {
        "authors": [
          "B S Hoppe"
        ],
        "doi": "10.1038/bmt.2008.408",
        "issue": "12",
        "unstructured": "Hoppe BS, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-call lymphoma. Bone Marrow Transplant. 2009;43(12):941–8.",
        "volume": "43"
      },
      "index": 15,
      "key": "36_CR1007",
      "locator": "941",
      "year": 2009
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "SJ Horning"
        ],
        "doi": "10.1200/jco.2004.06.088",
        "unstructured": "Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol. 2004;22:3032–8.",
        "volume": "22"
      },
      "index": 16,
      "key": "36_CR13",
      "locator": "3032",
      "year": 2004
    },
    {
      "container_name": "Lancet Oncol",
      "extra": {
        "authors": [
          "PJ Hoskin"
        ],
        "doi": "10.1016/s1470-2045(14)70036-1",
        "unstructured": "Hoskin PJ, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomized phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–63.",
        "volume": "15"
      },
      "index": 17,
      "key": "36_CR14",
      "locator": "457",
      "year": 2014
    },
    {
      "container_name": "Blood",
      "extra": {
        "authors": [
          "E Hoster"
        ],
        "doi": "10.1182/blood-2007-06-095331",
        "unstructured": "Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.",
        "volume": "111"
      },
      "index": 18,
      "key": "36_CR15",
      "locator": "558",
      "year": 2008
    },
    {
      "container_name": "International Journal of Radiation Oncology*Biology*Physics",
      "extra": {
        "authors": [
          "Tim Illidge"
        ],
        "doi": "10.1016/j.ijrobp.2014.01.006",
        "unstructured": "Illidge T, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. IJROBP. 2014;89(1):49–58.",
        "volume": "89"
      },
      "index": 19,
      "key": "36_CR1009",
      "locator": "49",
      "year": 2014
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "NA Johnson"
        ],
        "doi": "10.1200/jco.2011.41.0985",
        "issue": "28",
        "unstructured": "Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoa treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9.",
        "volume": "30"
      },
      "index": 20,
      "key": "36_CR16",
      "locator": "3452",
      "year": 2012
    },
    {
      "extra": {
        "unstructured": "Lamy T, Damaj G, Gyan E et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-3 trial from the Lysa/Goelams Group. Abstract 393. 2014 ASH Annual Meeting."
      },
      "index": 21,
      "key": "36_CR17"
    },
    {
      "container_name": "Radiother Oncol",
      "extra": {
        "authors": [
          "L Lowry"
        ],
        "doi": "10.1016/j.radonc.2011.05.013",
        "unstructured": "Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomized phase III trial. Radiother Oncol. 2011;100(1):86–92.",
        "volume": "100"
      },
      "index": 22,
      "key": "36_CR18",
      "locator": "86",
      "year": 2011
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "MP Mac Manus"
        ],
        "doi": "10.1200/jco.1996.14.4.1282",
        "unstructured": "Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282–90.",
        "volume": "14"
      },
      "index": 23,
      "key": "36_CR19",
      "locator": "1282",
      "year": 1996
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "TP Miller"
        ],
        "doi": "10.1056/nejm199807023390104",
        "unstructured": "Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21–6.",
        "volume": "339"
      },
      "index": 24,
      "key": "36_CR20",
      "locator": "21",
      "year": 1998
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "N Milpied"
        ],
        "doi": "10.1056/nejmoa031770",
        "unstructured": "Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–95.",
        "volume": "350"
      },
      "index": 25,
      "key": "36_CR21",
      "locator": "1287",
      "year": 2004
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "F Morschhauser"
        ],
        "doi": "10.1200/jco.2008.17.2015",
        "issue": "32",
        "unstructured": "Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156–64.",
        "volume": "26"
      },
      "index": 26,
      "key": "36_CR22",
      "locator": "5156",
      "year": 2008
    },
    {
      "container_name": "Lancet Oncol",
      "extra": {
        "authors": [
          "M Pfreundschuh"
        ],
        "doi": "10.1016/s1470-2045(06)70664-7",
        "unstructured": "Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91."
      },
      "index": 27,
      "key": "36_CR24",
      "locator": "379",
      "year": 2006
    },
    {
      "container_name": "Lancet Oncol",
      "extra": {
        "authors": [
          "M Pfreundschuh"
        ],
        "doi": "10.1016/s1470-2045(08)70002-0",
        "unstructured": "Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16."
      },
      "index": 28,
      "key": "36_CR25",
      "locator": "105",
      "year": 2008
    },
    {
      "container_name": "Lancet Oncol",
      "extra": {
        "authors": [
          "M Pfreundschuh"
        ],
        "doi": "10.1016/s1470-2045(11)70235-2",
        "issue": "11",
        "unstructured": "Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22.",
        "volume": "12"
      },
      "index": 29,
      "key": "36_CR26",
      "locator": "1013",
      "year": 2011
    },
    {
      "container_name": "J Clin Oncol",
      "extra": {
        "authors": [
          "M Pfreundschuh"
        ],
        "doi": "10.1200/jco.2004.22.14_suppl.6500",
        "unstructured": "Pfreundschuh M, Trümper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. J Clin Oncol. 2004;22:6500.",
        "volume": "22"
      },
      "index": 30,
      "key": "36_CR23",
      "locator": "6500",
      "year": 2004
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "T Philip"
        ],
        "doi": "10.1056/nejm199512073332305",
        "unstructured": "Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–5.",
        "volume": "333"
      },
      "index": 31,
      "key": "36_CR27",
      "locator": "1540",
      "year": 1995
    },
    {
      "container_name": "Journal of Clinical Oncology",
      "extra": {
        "authors": [
          "Jack Phan"
        ],
        "doi": "10.1200/jco.2009.27.3441",
        "issue": "27",
        "unstructured": "Phan J, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170–6.",
        "volume": "28"
      },
      "index": 32,
      "key": "36_CR1003",
      "locator": "4170",
      "year": 2010
    },
    {
      "container_name": "Leukemia & Lymphoma",
      "extra": {
        "authors": [
          "Oreofe O. Odejide"
        ],
        "doi": "10.3109/10428194.2014.930853",
        "unstructured": "Odejide OO, et al. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015;56(3):716–24.",
        "volume": "56"
      },
      "index": 33,
      "key": "36_CR1004",
      "locator": "716",
      "year": 2014
    },
    {
      "container_name": "N Engl J Med",
      "extra": {
        "authors": [
          "F Reyes"
        ],
        "doi": "10.1056/nejmoa042040",
        "unstructured": "Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–205.",
        "volume": "352"
      },
      "index": 34,
      "key": "36_CR28",
      "locator": "1197",
      "year": 2005
    },
    {
      "container_name": "Lancet",
      "extra": {
        "authors": [
          "MJ Rummel"
        ],
        "doi": "10.1016/s0140-6736(12)61763-2",
        "issue": "9873",
        "unstructured": "Rummel MJ, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomized, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.",
        "volume": "381"
      },
      "index": 35,
      "key": "36_CR29",
      "locator": "1203",
      "year": 2013
    },
    {
      "extra": {
        "unstructured": "Spier CM, LeBlanc M, Chase E, et al. Histologic subtypes do not confer unique outcomes in early-stage lymphoma: long-term follow-up of SWOG 8736. Blood. 2004;104. abst 3263."
      },
      "index": 36,
      "key": "36_CR30"
    },
    {
      "container_name": "Journal of Clinical Oncology",
      "extra": {
        "authors": [
          "Deborah M. Stephens"
        ],
        "doi": "10.1200/jco.2015.65.4582",
        "issue": "25",
        "unstructured": "Stephens DM, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. JCO. 2016;34(25):2997–3004.",
        "volume": "34"
      },
      "index": 37,
      "key": "36_CR1002",
      "locator": "2997",
      "year": 2016
    },
    {
      "extra": {
        "unstructured": "The International Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–94."
      },
      "index": 38,
      "key": "36_CR31"
    },
    {
      "container_name": "Cancer",
      "extra": {
        "authors": [
          "John A. Vargo"
        ],
        "doi": "10.1002/cncr.29491",
        "issue": "18",
        "unstructured": "Vargo JA, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325–34.",
        "volume": "121"
      },
      "index": 39,
      "key": "36_CR1001",
      "locator": "3325",
      "year": 2015
    },
    {
      "extra": {
        "unstructured": "Vitolo U et al. First-Line Treatment for primary testicular diffuse large B-cell lymphoa with rituximab-CHOP, CNS prophylaxis and contralateral testis irradiation: Final results of an international phase II trial. JCO 2011;29(20):2766–72."
      },
      "index": 40,
      "key": "36_CR2011"
    }
  ],
  "release_stage": "published",
  "release_type": "chapter",
  "release_year": 2018,
  "revision": "8c501ded-7634-4e33-8b58-a68f40ef32db",
  "state": "active",
  "title": "Non-Hodgkin's Lymphoma",
  "work_id": "bt2hjafnpfaftni5ruxrixvl3u"
}